Accretion Pharmaceuticals IPO opens for subscription: Price band, GMP among key details to know
initial public offering
(IPO) for subscription today, May 14. The IPO, which is set to close on May 16, aims to raise Rs 29.75 crore through a fresh issue of 29.46 lakh equity shares. Ahead of the issue opening, the GMP is muted at Rs 0.
The IPO follows a book-building process and will be listed on the NSE SME platform. Jawa Capital Services is the book-running lead manager for the issue, while
Kfin Technologies
is acting as the registrar. Gretex Share Broking has been appointed as the market maker for the IPO.
The company plans to utilize the IPO proceeds for multiple purposes, including capital expenditure towards purchasing new equipment and upgrading its existing manufacturing facility. Part of the funds will also be used for repaying certain borrowings, funding working capital requirements, and meeting general corporate expenses.
The allotment of shares is expected to be finalized on May 19, with refunds initiated on May 20, and shares credited to demat accounts the same day. The company is set to make its debut on the NSE SME platform on May 21.
Accretion Pharmaceuticals IPO price band
The price band for the IPO has been set at Rs 96 to Rs 101 per share, and investors can bid for a minimum of 1,200 shares, amounting to a minimum investment of Rs 1,15,200.
About Accretion Pharmaceuticals
Accretion Pharmaceuticals, a Gujarat-based pharmaceutical company, is engaged in the manufacturing and sale of a wide range of healthcare products, including tablets, capsules, oral liquids, external preparations, and Ayurvedic and herbal products.
The company also offers contract manufacturing services to its clients. Its manufacturing facility is located in Ahmedabad, Sanand, Gujarat.
Financials
Financially, Accretion Pharmaceuticals has shown strong growth. As of December 2024, the company reported total revenue of Rs 35.75 crore and a profit after tax (PAT) of Rs 5.24 crore. Its net worth stood at Rs 13.58 crore.
(
Disclaimer
: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
a few seconds ago
- Mint
Aurobindo Pharma expects China plant to break even at EBITDA level this year
New Delhi, Aurobindo Pharma expects its China facility to break even in the third quarter of the current financial year, according to its CFO Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up production. "This facility with an initial capacity of 2 billion units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the EBITDA level by Q3 FY26," Subramanian said in an analyst call. He noted that around USD 145 million has been invested in the facility, which commenced production and invoicing in Q4 FY25 and Q1 FY26, respectively. Elaborating on other investments, Subramanian said the company has invested about USD 70 million in two US facilities, with production expected to start in the current fiscal year. Elaborating further, he noted that the company plans to file for more than 20 products in the US and Europe from its Eugia-V plant in Visakhapatnam. He noted that the company has invested around USD 30 million in the Biologics CMO business so far, and the balance of USD 100 million plus capital is expected to be invested by March 2027. On business outlook, Subramanian stated: "Looking ahead, we remain optimistic about sustaining our growth momentum. Our confidence is supported by expected volume expansion, continued product launches and a stable pricing environment, especially in the US and Europe". Commercial operations ramping up at new manufacturing sites would further support the topline growth and margin improvement in the upcoming quarters, he added. "We are confident of achieving our internal target margin of 20-21 per cent in FY26," Subramanian stated. Aurobindo Pharma reported a 10 per cent year-on-year dip in its consolidated net profit to ₹ 824 crore for the June quarter, due to a fall in sales in the US and I business vertical. Its revenue from operations increased to ₹ 7,868 crore for the June quarter against ₹ 7,567 crore in the year-ago period. This article was generated from an automated news agency feed without modifications to text.
&w=3840&q=100)
Business Standard
a few seconds ago
- Business Standard
Listing a reality, possible in 12-18 months: Classic Legends MD Thareja
The public listing of Mahindra group-backed Classic Legends, the maker of iconic brands Yezdi, Jawa and BSA, is a reality, and a timeline of 12-18 months is a possibility, as it seeks to create a credible mid-market global brand, according to its MD and co-founder Anupam Thareja. The company -- which has an R&D centre for electric vehicles in the UK, supported by the government there -- is ready with its electric motorcycle, but will launch it only when the market is ready, especially in terms of charging infrastructure, he told PTI. When asked if a public listing of Classic Legends is on the distant horizon, Thareja said, "Not at all. In fact, you will be happy and surprised that we just gave stock also have investors in this company. So listing is a reality, and it has nothing to do with unlocking shareholder value. It is the way this is constructed. This is a global company we are creating". Stressing that the company chose to launch the BSA brand first in the UK and then in India, he said, "That is audacity, that is the belief (that we have)...the world needs a credible mid-market motorcycle brand..." He further said,"...we (will) need capital in the future, but should we have a listed vehicle? 100 per cent and that's not in the distant future by the way". When asked if the listing can happen in the next 12-18 months, Thareja said, "I don't have the desperate need to raise capital. We are sitting on Rs 875 crore of capital. So, I'm not going to do it just for money, but will it happen in 12 to 18 months? Why not, of course". On the company's electric vehicle plans, Thareja said, "We are ready with our (electric) bike, we can launch as soon as we want, but I don't think the market is ready". Elaborating, he said, for the type of bikes Classic Legends is into, long range (battery) is required, but battery packs are still expensive, and there are multiple issues related to charging infrastructure and availability of retail financing for electric motorcycles. He said electric adoption in two-wheelers will be first seen in scooters, followed by commuters, and the premium 'classics' segment is expected to be the last. Thareja said Classic Legends has "had a very deep relationship" with the UK government, which gave the company 50 per cent grant, under which "whatever money we put they will give us equal money as a grant to set up an electric R&D unit in the UK. That is running and we have an engineering segment in Coventry, which is making electric bikes". There is a very high probability that the UK will be the first market where the electric bike will be first launched, he said without disclosing details. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
&w=3840&q=100)
Business Standard
a few seconds ago
- Business Standard
Aurobindo Pharma expects China plant to break even at Ebidta level in FY26
Aurobindo Pharma expects its China facility to break even in the third quarter of the current financial year, according to its CFO Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up production. "This facility with an initial capacity of 2 billion units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the Ebidta (earnings before interest, taxes, depreciation, and amortisation) level by Q3 FY26," Subramanian said in an analyst call. He noted that around $145 million has been invested in the facility, which commenced production and invoicing in Q4 FY25 and Q1 FY26, respectively. Elaborating on other investments, Subramanian said the company has invested about $70 million in two US facilities, with production expected to start in the current fiscal year. Elaborating further, he noted that the company plans to file for more than 20 products in the US and Europe from its Eugia-V plant in Visakhapatnam. He noted that the company has invested around $30 million in the Biologics CMO business so far, and the balance of $100 million plus capital is expected to be invested by March 2027. On business outlook, Subramanian stated: "Looking ahead, we remain optimistic about sustaining our growth momentum. Our confidence is supported by expected volume expansion, continued product launches and a stable pricing environment, especially in the US and Europe". Commercial operations ramping up at new manufacturing sites would further support the topline growth and margin improvement in the upcoming quarters, he added. "We are confident of achieving our internal target margin of 20-21 per cent in FY26," Subramanian stated. Aurobindo Pharma reported a 10 per cent year-on-year dip in its consolidated net profit to ₹824 crore for the June quarter, due to a fall in sales in the US and API business vertical. Its revenue from operations increased to ₹7,868 crore for the June quarter against ₹7,567 crore in the year-ago period.
